BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hoffmann J, Supronsinchai W, Akerman S, Andreou AP, Winrow CJ, Renger J, Hargreaves R, Goadsby PJ. Evidence for orexinergic mechanisms in migraine. Neurobiology of Disease 2015;74:137-43. [DOI: 10.1016/j.nbd.2014.10.022] [Cited by in Crossref: 50] [Cited by in F6Publishing: 43] [Article Influence: 7.1] [Reference Citation Analysis]
Number Citing Articles
1 Grewal P, Smith JH. When Headache Warns of Homeostatic Threat: the Metabolic Headaches. Curr Neurol Neurosci Rep 2017;17. [DOI: 10.1007/s11910-017-0714-5] [Cited by in Crossref: 2] [Article Influence: 0.4] [Reference Citation Analysis]
2 Tsuneki H, Wada T, Sasaoka T. Chronopathophysiological implications of orexin in sleep disturbances and lifestyle-related disorders. Pharmacology & Therapeutics 2018;186:25-44. [DOI: 10.1016/j.pharmthera.2017.12.010] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
3 González-hernández A, Condés-lara M, García-boll E, Villalón CM. An outlook on the trigeminovascular mechanisms of action and side effects concerns of some potential neuropeptidergic antimigraine therapies. Expert Opinion on Drug Metabolism & Toxicology 2021;17:179-99. [DOI: 10.1080/17425255.2021.1856366] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
4 Goadsby PJ. Bench to bedside advances in the 21st century for primary headache disorders: migraine treatments for migraine patients. Brain 2016;139:2571-7. [PMID: 27671024 DOI: 10.1093/brain/aww236] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 5.0] [Reference Citation Analysis]
5 Song TJ, Yun CH, Cho SJ, Kim WJ, Yang KI, Chu MK. Short sleep duration and poor sleep quality among migraineurs: A population-based study. Cephalalgia 2018;38:855-64. [PMID: 28641451 DOI: 10.1177/0333102417716936] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 3.6] [Reference Citation Analysis]
6 Zorina-lichtenwalter K, Meloto C, Khoury S, Diatchenko L. Genetic predictors of human chronic pain conditions. Neuroscience 2016;338:36-62. [DOI: 10.1016/j.neuroscience.2016.04.041] [Cited by in Crossref: 91] [Cited by in F6Publishing: 69] [Article Influence: 15.2] [Reference Citation Analysis]
7 Karsan N, Bose P, Goadsby PJ. The Migraine Premonitory Phase. Continuum (Minneap Minn) 2018;24:996-1008. [PMID: 30074545 DOI: 10.1212/CON.0000000000000624] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
8 Ogunlaja O, Karsan N, Goadsby P. Emerging drugs for the prevention of migraine. Expert Opin Emerg Drugs 2021;26:271-80. [PMID: 34263680 DOI: 10.1080/14728214.2021.1956463] [Reference Citation Analysis]
9 Rozen TD. Cluster Headache Clinical Phenotypes: Tobacco Nonexposed (Never Smoker and No Parental Secondary Smoke Exposure as a Child) versus Tobacco-Exposed: Results from the United States Cluster Headache Survey. Headache 2018;58:688-99. [PMID: 29536529 DOI: 10.1111/head.13295] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
10 Kowalska M, Prendecki M, Kozubski W, Lianeri M, Dorszewska J. Molecular factors in migraine. Oncotarget 2016;7:50708-18. [PMID: 27191890 DOI: 10.18632/oncotarget.9367] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 6.3] [Reference Citation Analysis]
11 Strother LC, Srikiatkhachorn A, Supronsinchai W. Targeted Orexin and Hypothalamic Neuropeptides for Migraine. Neurotherapeutics 2018;15:377-90. [PMID: 29442286 DOI: 10.1007/s13311-017-0602-3] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 8.0] [Reference Citation Analysis]
12 Valade D. [New horizons for acute and prophylactic treatments of migraine]. Biol Aujourdhui 2019;213:59-64. [PMID: 31274104 DOI: 10.1051/jbio/2019021] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
13 Ong JJY, Wei DY, Goadsby PJ. Recent Advances in Pharmacotherapy for Migraine Prevention: From Pathophysiology to New Drugs. Drugs 2018;78:411-37. [PMID: 29396834 DOI: 10.1007/s40265-018-0865-y] [Cited by in Crossref: 37] [Cited by in F6Publishing: 24] [Article Influence: 12.3] [Reference Citation Analysis]
14 Altamura C, Corbelli I, de Tommaso M, Di Lorenzo C, Di Lorenzo G, Di Renzo A, Filippi M, Jannini TB, Messina R, Parisi P, Parisi V, Pierelli F, Rainero I, Raucci U, Rubino E, Sarchielli P, Li L, Vernieri F, Vollono C, Coppola G. Pathophysiological Bases of Comorbidity in Migraine. Front Hum Neurosci 2021;15:640574. [PMID: 33958992 DOI: 10.3389/fnhum.2021.640574] [Reference Citation Analysis]
15 Kowalska M, Kapelusiak-Pielok M, Grzelak T, Wypasek E, Kozubski W, Dorszewska J. The New *G29A and G1222A of HCRTR1, 5-HTTLPR of SLC6A4 Polymorphisms and Hypocretin-1, Serotonin Concentrations in Migraine Patients. Front Mol Neurosci 2018;11:191. [PMID: 29922128 DOI: 10.3389/fnmol.2018.00191] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
16 Goadsby PJ. Putting migraine to sleep: Rexants as a preventive strategy. Cephalalgia 2015;35:377-8. [DOI: 10.1177/0333102414566196] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
17 Hoffmann J, May A. Diagnosis, pathophysiology, and management of cluster headache. Lancet Neurol. 2018;17:75-83. [PMID: 29174963 DOI: 10.1016/s1474-4422(17)30405-2] [Cited by in Crossref: 106] [Cited by in F6Publishing: 32] [Article Influence: 21.2] [Reference Citation Analysis]
18 Lovati C, Giani L, D'Amico D, Mariani C. Sleep, headaches and cerebral energy control: a synoptic view. Expert Rev Neurother 2017;17:239-50. [PMID: 27547918 DOI: 10.1080/14737175.2016.1226133] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
19 Bertels Z, Pradhan AAA. Emerging Treatment Targets for Migraine and Other Headaches. Headache 2019;59 Suppl 2:50-65. [PMID: 31291018 DOI: 10.1111/head.13585] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
20 Recinella L, Chiavaroli A, di Giacomo V, Antolini MD, Acquaviva A, Leone S, Brunetti L, Menghini L, Ak G, Zengin G, Di Simone SC, Ferrante C, Orlando G. Anti-Inflammatory and Neuromodulatory Effects Induced by Tanacetum parthenium Water Extract: Results from In Silico, In Vitro and Ex Vivo Studies. Molecules 2020;26:E22. [PMID: 33374525 DOI: 10.3390/molecules26010022] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
21 Kim SH, Park JY, Shin HE, Lee SB, Ryu DW, Kim TW, Park JW. The influence of rapid eye movement sleep deprivation on nociceptive transmission and the duration of facial allodynia in rats: a behavioral and Fos immunohistochemical study. J Headache Pain 2019;20:21. [PMID: 30823867 DOI: 10.1186/s10194-019-0977-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
22 Schulte LH, Mehnert J, May A. Longitudinal Neuroimaging over 30 Days: Temporal Characteristics of Migraine. Ann Neurol 2020;87:646-51. [DOI: 10.1002/ana.25697] [Cited by in Crossref: 24] [Cited by in F6Publishing: 17] [Article Influence: 12.0] [Reference Citation Analysis]
23 Ashina M, Doležil D, Bonner JH, Zhou L, Klatt J, Picard H, Mikol DD. A phase 2, randomized, double-blind, placebo-controlled trial of AMG 301, a pituitary adenylate cyclase-activating polypeptide PAC1 receptor monoclonal antibody for migraine prevention. Cephalalgia 2021;41:33-44. [PMID: 33231489 DOI: 10.1177/0333102420970889] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
24 Levine A, Vanderah TW, Largent-Milnes TM. An underrepresented majority: A systematic review utilizing allodynic criteria to examine the present scarcity of discrete animal models for episodic migraine. Cephalalgia 2021;41:404-16. [PMID: 33131303 DOI: 10.1177/0333102420966984] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
25 Goadsby PJ, Holland PR, Martins-Oliveira M, Hoffmann J, Schankin C, Akerman S. Pathophysiology of Migraine: A Disorder of Sensory Processing. Physiol Rev 2017;97:553-622. [PMID: 28179394 DOI: 10.1152/physrev.00034.2015] [Cited by in Crossref: 570] [Cited by in F6Publishing: 485] [Article Influence: 114.0] [Reference Citation Analysis]
26 Suzuki K, Miyamoto M, Miyamoto T, Inoue Y, Matsui K, Nishida S, Hayashida K, Usui A, Ueki Y, Nakamura M, Murata M, Numao A, Watanabe Y, Suzuki S, Hirata K. The Prevalence and Characteristics of Primary Headache and Dream-Enacting Behaviour in Japanese Patients with Narcolepsy or Idiopathic Hypersomnia: A Multi-Centre Cross-Sectional Study. PLoS One 2015;10:e0139229. [PMID: 26418536 DOI: 10.1371/journal.pone.0139229] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
27 Lambru G, Andreou AP, Guglielmetti M, Martelletti P. Emerging drugs for migraine treatment: an update. Expert Opin Emerg Drugs 2018;23:301-18. [PMID: 30484333 DOI: 10.1080/14728214.2018.1552939] [Cited by in Crossref: 32] [Cited by in F6Publishing: 23] [Article Influence: 8.0] [Reference Citation Analysis]
28 May A. Understanding migraine as a cycling brain syndrome: reviewing the evidence from functional imaging. Neurol Sci 2017;38:125-30. [DOI: 10.1007/s10072-017-2866-0] [Cited by in Crossref: 54] [Cited by in F6Publishing: 49] [Article Influence: 10.8] [Reference Citation Analysis]
29 Do TP, Al-Saoudi A, Ashina M. Future prophylactic treatments in migraine: Beyond anti-CGRP monoclonal antibodies and gepants. Rev Neurol (Paris) 2021:S0035-3787(21)00610-X. [PMID: 34294458 DOI: 10.1016/j.neurol.2021.06.005] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
30 Messina A, Bitetti I, Precenzano F, Iacono D, Messina G, Roccella M, Parisi L, Salerno M, Valenzano A, Maltese A, Salerno M, Sessa F, Albano GD, Marotta R, Villano I, Marsala G, Zammit C, Lavano F, Monda M, Cibelli G, Lavano SM, Gallai B, Toraldo R, Monda V, Carotenuto M. Non-Rapid Eye Movement Sleep Parasomnias and Migraine: A Role of Orexinergic Projections. Front Neurol 2018;9:95. [PMID: 29541053 DOI: 10.3389/fneur.2018.00095] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
31 May A, Burstein R. Hypothalamic regulation of headache and migraine. Cephalalgia 2019;39:1710-9. [PMID: 31466456 DOI: 10.1177/0333102419867280] [Cited by in Crossref: 35] [Cited by in F6Publishing: 28] [Article Influence: 11.7] [Reference Citation Analysis]
32 Schuster NM, Rapoport AM. New strategies for the treatment and prevention of primary headache disorders. Nat Rev Neurol 2016;12:635-50. [PMID: 27786243 DOI: 10.1038/nrneurol.2016.143] [Cited by in Crossref: 56] [Cited by in F6Publishing: 49] [Article Influence: 14.0] [Reference Citation Analysis]
33 Akerman S, Romero-reyes M, Holland PR. Current and novel insights into the neurophysiology of migraine and its implications for therapeutics. Pharmacology & Therapeutics 2017;172:151-70. [DOI: 10.1016/j.pharmthera.2016.12.005] [Cited by in Crossref: 37] [Cited by in F6Publishing: 34] [Article Influence: 7.4] [Reference Citation Analysis]
34 Burstein R, Noseda R, Borsook D. Migraine: multiple processes, complex pathophysiology. J Neurosci. 2015;35:6619-6629. [PMID: 25926442 DOI: 10.1523/jneurosci.0373-15.2015] [Cited by in Crossref: 317] [Cited by in F6Publishing: 123] [Article Influence: 45.3] [Reference Citation Analysis]
35 Tiseo C, Vacca A, Felbush A, Filimonova T, Gai A, Glazyrina T, Hubalek IA, Marchenko Y, Overeem LH, Piroso S, Tkachev A, Martelletti P, Sacco S; European Headache Federation School of Advanced Studies (EHF-SAS). Migraine and sleep disorders: a systematic review. J Headache Pain 2020;21:126. [PMID: 33109076 DOI: 10.1186/s10194-020-01192-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
36 Suzuki K, Okuma Y, Uchiyama T, Miyamoto M, Sakakibara R, Shimo Y, Hattori N, Kuwabara S, Yamamoto T, Kaji Y, Hirano S, Suzuki S, Haruyama Y, Kobashi G, Hirata K; Kanto NMPD investigators. The prevalence, course and clinical correlates of migraine in Parkinson's disease: A multicentre case-controlled study. Cephalalgia 2018;38:1535-44. [PMID: 29073773 DOI: 10.1177/0333102417739302] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
37 Martins-Oliveira M, Akerman S, Holland PR, Hoffmann JR, Tavares I, Goadsby PJ. Neuroendocrine signaling modulates specific neural networks relevant to migraine. Neurobiol Dis 2017;101:16-26. [PMID: 28108291 DOI: 10.1016/j.nbd.2017.01.005] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 4.4] [Reference Citation Analysis]
38 Vila-Pueyo M, Hoffmann J, Romero-Reyes M, Akerman S. Brain structure and function related to headache: Brainstem structure and function in headache. Cephalalgia 2019;39:1635-60. [PMID: 29969040 DOI: 10.1177/0333102418784698] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
39 Martins-Oliveira M, Tavares I, Goadsby PJ. Was it something I ate? Understanding the bidirectional interaction of migraine and appetite neural circuits. Brain Res 2021;1770:147629. [PMID: 34428465 DOI: 10.1016/j.brainres.2021.147629] [Reference Citation Analysis]
40 Ferroni P, Barbanti P, Della-Morte D, Palmirotta R, Jirillo E, Guadagni F. Redox Mechanisms in Migraine: Novel Therapeutics and Dietary Interventions. Antioxid Redox Signal 2018;28:1144-83. [PMID: 28990418 DOI: 10.1089/ars.2017.7260] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
41 Hoffmann J, Baca SM, Akerman S. Neurovascular mechanisms of migraine and cluster headache. J Cereb Blood Flow Metab 2019;39:573-94. [PMID: 28948863 DOI: 10.1177/0271678X17733655] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 3.4] [Reference Citation Analysis]
42 Karsan N, Gonzales EB, Dussor G. Targeted Acid-Sensing Ion Channel Therapies for Migraine. Neurotherapeutics 2018;15:402-14. [PMID: 29549622 DOI: 10.1007/s13311-018-0619-2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
43 Schulte LH, May A. Of generators, networks and migraine attacks. Current Opinion in Neurology 2017;30:241-5. [DOI: 10.1097/wco.0000000000000441] [Cited by in Crossref: 26] [Cited by in F6Publishing: 11] [Article Influence: 5.2] [Reference Citation Analysis]
44 Moreno-Ajona D, Villar-Martínez MD, Goadsby PJ. Targets for migraine treatment: beyond calcitonin gene-related peptide. Curr Opin Neurol 2021;34:363-72. [PMID: 33840777 DOI: 10.1097/WCO.0000000000000935] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
45 Pavkovic IM, Kothare SV. Migraine and Sleep in Children: A Bidirectional Relationship. Pediatric Neurology 2020;109:20-7. [DOI: 10.1016/j.pediatrneurol.2019.12.013] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]